

<i>Product Licence Number</i>	<i>Company Name</i>	<i>Product Name</i>	<i>Active Ingredients</i>	<i>Indications</i>	<i>Date of Authorisation</i>
00037/0269	Abbott Laboratories Limited	Iopamidol Injection 200 mg/ml	Iopamidol 408-000 mg/ml	X-ray contrast media for lumbar and thoracocervical myelography, cerebral angiography, peripheral arteriography and venography, angiocardiology, digital subtraction angiography, left ventriculography and coronary arteriography, aortography, selective visceral angiography, computer tomography enhancement, urography, arthrography. Prescription Only Medicine (See PL00037/0269)	15th July 1997
00037/0270	Abbott Laboratories Limited	Iopamidol Injection 300 mg/ml	Iopamidol 612-000 mg/ml	Prescription Only Medicine (See PL 00037/0269)	15th July 1997
00037/0271	Abbott Laboratories Limited	Iopamidol Injection 370 mg/ml	Iopamidol 755-000 mg/ml	Prescription Only Medicine (See PL 00037/0269)	15th July 1997
00063/0099	Reckitt & Colman Products Limited	Gaviscon Infant	Magnesium Alginate 87-500 mg Sodium Alginate 225-000 mg	Helps to prevent gastric regurgitation in infants where competence of the cardiac sphincter has not been fully established. The indications for use are gastric regurgitation, gastro-oesophageal reflux and reflux associated with hiatus hernia in infants and young children. Pharmacy Medicine	21st April 1997
00065/0146	Organon Laboratories Limited	Livial 2.5 mg Tablets	Tibolone 2-500 mg	In oestrogen deficiency states for the treatment of vasomotor symptoms (such as hot flushes and sweating), depressed mood, decreased libido and prevention of osteoporosis in women at risk of developing fractures. However at present there is no established screening programme for determining women at risk of developing osteoporosis and osteoporotic fractures. Epidemiological studies suggest a number of individual risk factors which contribute to the development of postmenopausal osteoporosis. These include early menopause, family history of osteoporosis, thinness, small frame, cigarette use and recent prolonged systemic corticosteroid use. If several of these risk factors are present in a patient, consideration should be given to hormone replacement therapy. Prescription Only Medicine	21st April 1997
00095/0311	Cyanamid of Great Britain Ltd.	Prostap 3 Leuporelin Acetate Depot Injection 11-25 mg	Leuporelin Acetate 11-250 mg	Prostap 3 is indicated for use in the management of advanced prostatic cancer. Prescription Only Medicine	24th April 1997
00101/0451	Novartis Pharmaceuticals UK Ltd.	Slow Sodium Tablets 600 mg	Sodium Chloride EP 600-00 mg	Treatment and Prophylaxis of Sodium Chloride Deficiency General Sales List	4th July 1997
00142/0394	A H Cox & Company Limited	Oxybutynin Hydrochloride Tablets 5 mg	Oxybutynin Hydrochloride 5-000 mg	(1) Indicated for urinary incontinence, urgency and frequency in unstable bladder conditions due either to idiopathic detrusor instability or neurogenic bladder disorders (detrusor hyperreflexia) in conditions such as spina bifida and multiple sclerosis. (2) Children over 5 years of age: in addition to neurogenic bladder disorders oxybutynin may be used in nocturnal enuresis in conjunction with other non-drug therapy where this alone, or in conjunction with other drug treatment, has failed. Prescription Only Medicine	10th July 1997
00142/0404	A H Cox & Company Limited	Ranitidine Tablets BP 150 mg	Ranitidine Hydrochloride 167-390 mg	(1) For the treatment of duodenal ulcer and benign gastric ulcer, including that associated with non-steroidal anti-inflammatory agents. (2) For the prevention of NSAID associated duodenal ulcers. (3) For the treatment of post-operative ulcer, Zollinger-Ellison syndrome and oesophageal reflux disease including the long term management of healed oesophagitis. Other patients with chronic episodic dyspepsia, characterised by pain (epigastric or retrosternal) which is related to meals or disturbs sleep but is not associated with the preceding conditions may benefit from Ranitidine treatment. (4) For the following conditions where reduction of gastric secretion and acid output is desirable: the prophylaxis of gastrointestinal haemorrhage from stress ulceration in seriously ill patients; the prophylaxis of recurrent haemorrhage in patients	11th July 1997